ghk-cu third party tested GHK Copper Peptide | Research Peptide — UNYX PeptidesUNYX

PDRN inhibits melanogenesis through downregulation of microphthalmia-associated transcription factor (MITF), and the 2024 Tsai split-face RCT demonstrated significant melasma severity reduction with combined microneedling radiofrequency and depigmenting agents in Fitzpatrick III and IV patients

0.1 mL delivers the same dose at a higher concentration

More injections per session, but full dose control over each compound

200% Money-Back Guarantee Test our product if purity doesn't match the label, we refund 200%

For research applications Research use may require different concentrations based on experimental protocols

If the committee votes favorably and the FDA adopts the recommendation, BPC-157 could return to Category 1 status, allowing 503A compounding pharmacies to prepare it against valid prescriptions